BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24072401)

  • 1. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
    Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
    Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
    Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
    Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
    Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
    J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
    Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
    Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
    Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
    Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
    PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
    Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
    Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
    Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z
    Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.
    Gros A; Turcotte S; Wunderlich JR; Ahmadzadeh M; Dudley ME; Rosenberg SA
    Clin Cancer Res; 2012 Oct; 18(19):5212-23. PubMed ID: 22837179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
    Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
    Schilling B; Sucker A; Griewank K; Zhao F; Weide B; Görgens A; Giebel B; Schadendorf D; Paschen A
    Int J Cancer; 2013 Oct; 133(7):1653-63. PubMed ID: 23526263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
    Jiang H; Gebhardt C; Umansky L; Beckhove P; Schulze TJ; Utikal J; Umansky V
    Int J Cancer; 2015 May; 136(10):2352-60. PubMed ID: 25353097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.
    Jitschin R; Braun M; Büttner M; Dettmer-Wilde K; Bricks J; Berger J; Eckart MJ; Krause SW; Oefner PJ; Le Blanc K; Mackensen A; Mougiakakos D
    Blood; 2014 Jul; 124(5):750-60. PubMed ID: 24850760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
    Filipazzi P; Valenti R; Huber V; Pilla L; Canese P; Iero M; Castelli C; Mariani L; Parmiani G; Rivoltini L
    J Clin Oncol; 2007 Jun; 25(18):2546-53. PubMed ID: 17577033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased, but Functionally Impaired, CD14(+) HLA-DR(-/low) Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells.
    Soler DC; Young AB; Fiessinger L; Galimberti F; Debanne S; Groft S; McCormick TS; Cooper KD
    J Invest Dermatol; 2016 Apr; 136(4):798-808. PubMed ID: 26807516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.